TRIMB Healthcare

May 2015

BUYER

Swedish institutional and private investors.

TARGET

Trimb Healthcare holds a portfolio of over-the-counter (OTC) healthcare products treating and preventing conditions such as high cholesterol and blood glucose, red eyes, rhinitis, snoring and nosebleeds. Trimb’s most important product, Betavivo, is an oat-based product which is scientifically proven to reduce cholesterol and blood sugar levels without adverse effects. Betavivo is approved in the EU by EFSA.

TRANSACTION

Convertible issue to existing shareholders and a number of new Swedish institutional and private investors of SEK 55 million to fund further M&A opportunities of OTC products and companies.